key: cord-1049486-n6mxi3sb
authors: Rizzoli, L.; Collini, L.; Magnano, M.; Termine, S.; Barcelli, R.; Infusino, S.D.; Bauer, P.; Rech, G.; Girardelli, C. R.; Balestri, R.
title: Chilblain‐like lesions during COVID‐19 pandemic: a serological study on a case series
date: 2020-07-01
journal: Br J Dermatol
DOI: 10.1111/bjd.19348
sha: b77d785d66a7cf01b07f17a4c4c8fe54e8354fdf
doc_id: 1049486
cord_uid: n6mxi3sb

The outbreak of chilblain‐like lesions (CLL) coincidentally to the COVID‐19 pandemic is a topic of great concern. SARS‐CoV‐2 has been hypothesized as the etiologic agent of CLL, on the basis of the temporal correlation between the “burst” of skin manifestations and the viral pandemic. However, the relationship between CLL and COVID‐19 remains unclear, since authors failed to confirm the SARS‐CoV‐2 infection in these patients using a real‐time reverse transcription polymerase chain reaction (rt‐PCR) test from nasopharyngeal swabs, which seldom resulted positive. Indeed, the most recent articles on the prevalence of the SARS‐CoV‐2 infection in CLL reported a positive swab test in only about a fifth of these patients.

DEAR EDITOR, The outbreak of chilblain-like lesions (CLL) coincidentally to the COVID-19 pandemic is a topic of great concern. 1-6 SARS-CoV-2 has been hypothesized as the etiologic agent of CLL, on the basis of the temporal correlation between the "burst" of skin manifestations and the viral pandemic. However, the relationship between CLL and COVID-19 remains unclear, since authors failed to confirm the SARS-CoV-2 infection in these patients using a real-time reverse transcription polymerase chain reaction (rt-PCR) test from nasopharyngeal swabs, which seldom resulted positive. [1] [2] [3] [4] [5] Indeed, the most recent articles on the prevalence of the SARS-CoV-2 infection in CLL reported a positive swab test in only about a fifth of these patients. 4, 5 In a few cases, serological tests were used, but these initially-available tests were largely unreliable, since they had been rapidly developed and placed on the market with limited validation on clinical samples.

We collected a total of 16 patients presenting CLL, who were all negative to the nasopharyngeal swab. We then decided to re-call our patients to perform a recently developed rapid chromatographic immunoassay (RCI) for the qualitative detection of specific antibodies to SARS-CoV-2, using the SD Biosensor COVID-19 IgM/IgG Duo assay (SD Biosensor INC.,Yeongtonggu, REPUBLIC OF KOREA).

The SD Biosensor's package insert claims a sensitivity of 99.10% and a specificity of 95.09%, established in a retrospective, multi-center randomized, single-blinded study on 504 specimens, if used more than 14 days after the symptom onset.

A total of 12 patients accepted to undergo the RCI test; their characteristics are summarized in Table 1 . All of them were tested at least 14 days after the skin disease presentation (mean value: 51.25±25.83), according to the manufacturer's instructions. In 11/12 the presence of IgM or IgG was not detected. The sole patient with positive IgG was the only one with a history of exposure to a confirmed infected cohabitant. Four patients were also tested for other common viral infections, without significant results. This is the first study in which patients with CLL have been investigated with both rt-PCR nasopharyngeal swab and serologic RCI, after a sufficient time lapse to develop antibodies against SARS-CoV-2. Indeed, higher levels of IgM and IgG have been found in the second and third week Accepted Article of illness, then IgM begins to decline and almost disappears by week 7, while IgG persists. Their persistence still remains unknown, although data suggest a serological profile similar to SARS-CoV, which shows detectable IgG up to 24 months. 7 Therefore, while swabs are known to be associated with an elevated number of false negative results, serological tests may represent a reliable instrument to identify past infections. We observed a high prevalence of negative serologic results in CLL. These data, associated with the high prevalence of negative rt-PCR tests as seen in the literature, 4-5 raise two hypotheses: a) SARS-CoV-2 is not the etiologic agent of CLL.

In this case, we should consider another viral agent, and the presence of SARS-CoV-2 may therefore be only a casual finding. However, a viral outbreak during another viral pandemic seems improbable.

One of our cases presented the clinical onset of CLL some days before the first Italian recognized case of COVID-19. This could support the hypothesis of a different etiologic agent. On the other hand, the literature suggests that the SARS-CoV-2 virus had already appeared in northern Italy between the second half of January and early February 2020. 8 We also considered that these may be true chilblains, but this seems unlikely, as our patients had no personal history of chilblains or rheumatologic diseases and were forced to stay home during lockdown, avoiding external cold weather. Nevertheless, our regional meteorological station registered similar or higher temperatures during February, March and April 2020 compared to the mean temperatures of the past 13 years. b) SARS-CoV-2 is the etiologic agent of CLL, but does not induce detectable IgM/IgG.

In this case we can put forward two more hypotheses: i) the viral load was not enough to induce antibody formation; ii) the host developed an early and robust IFN-I response, muting early viral replication and not permitting the development of detectable IgM/IgG. 1 However, this would be in contrast with the hypothesis of delayed immune-mediated reaction to the virus in genetically-predisposed patients, formerly proposed. 1 The main limitation of our serologic study is the lack of independent validation of the available tests on the market, despite an excellent clinical performance in real life of the used assay (personal experience).

In conclusion, while our study confirms that acral skin lesions are not a specific marker of SARS-CoV-2 infection, 4 it is necessary not only to expand our observation by serologically testing a larger amount of CLL patients, but also to investigate etiologic agents other than SARS-CoV-2.

This article is protected by copyright. All rights reserved 

Late onset of acral necrosis after SARS-CoV-2 infection resolution

Characterization of acute acroischemic lesions in non-hospitalized patients: a case series of 132 patients during the COVID-19 outbreak

Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases

Are Chilblain-Like Acral Skin Lesions Really Indicative of COVID-19? A Prospective Study and Literature Review

Nunnari G Diversity of Clinical Appearance of Cutaneous Manifestations in the Course of COVID-19

Further evidence that chilblains are a cutaneous manifestation of COVID-19 infection

Interpreting Diagnostic Tests for SARS-CoV-2

Online ahead of print

Genomic Characterization and Phylogenetic Analysis of SARS-COV-2 in Italy

"The patients in this manuscript have given their written informed consent to the publication of their case details." "The authors thank the colleagues who contributed to collecting the cases (Roberta Maria Pandolfi, Gabriella Pravatà, Maria Cristina Sicher, Chiara Mattiucci), Alessandra Iadicicco and Erica Dolzan who performed the serological tests, and Paolo Lanzafame for his critical review. A special acknowledgement also goes to Dr Serena Giacomin, president of the Italian Climate Network, and Dr Filippo Orlando, who provided us with the meteorological data."